Apollo Endosurgery Inc
APEN
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
39.9% upsideUndervalued by 39.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $579.72 Million |
|---|---|
| Enterprise Value | $579.78 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.98 |
| Beta | 2.32 |
| Outstanding Shares | 30,243,264 |
Return
| Return on Equity | -122.23% |
|---|---|
| Return on Assets | -36.14% |
| Return on Invested Capital | -39.35% |
Valuation & Multiples
| P/E Ratio | -10.2 |
|---|---|
| PEG | 124.61 |
| Price to Sales | 5.0 |
| Price to Book Ratio | 10.0 |
| Enterprise Value to Revenue | 7.54 |
| Enterprise Value to EBIT | -20.84 |
| Enterprise Value to Net Income | -15 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | 1.75 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Apollo Endosurgery Inc
CEO: Gary Atkinson Relevant Senate Committees
Controls taxation, trade, and entitlement spending (Medicare/Medicaid), which directly impact corporate profitability, market access, and reimbursement for biological products in the healthcare system.
Directly regulates the FDA, which is responsible for the approval, manufacturing standards, and oversight of biological products, making it profoundly influential for Apollo Endosurgery.
Directly impacts the company through oversight of intellectual property rights (patents for biological products) and antitrust enforcement for potential mergers and acquisitions, both critical for the biotech sector.